Is GRI or GYRE more undervalued in 2026?

CirclFi compares GRI Bio, Inc. (GRI) and Gyre Therapeutics, Inc. (GYRE) using 13 institutional-grade valuation models. GRI has a Quality of Company score of 3.9/10 while GYRE scores 8.0/10.

Which is a better buy — GRI or GYRE?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do GRI and GYRE valuations compare?

GRI at $2.06 and GYRE at $5.91 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

GRI vs GYRE Valuation Comparison 2026 — Intrinsic Value Analysis

GRI

Pharmaceutical Preparations

GRI Bio, Inc.

Quality

3.9

out of 10

Value Trap

SAFE

Price

$2.06

Last close

Models

6/13

Active

GYRE

Pharmaceutical Preparations

Gyre Therapeutics, Inc.

Quality

8.0

out of 10

Value Trap

SAFE

Price

$5.91

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	GRI Fair Value	GRI Upside	GYRE Fair Value	GYRE Upside
Bayesian DCF	Intrinsic	$3.99	+93.7%	$0.52	-91.2%
Earnings Power Value	Intrinsic	—	—	$0.74	-87.4%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.05	-97.9%	$1.15	-80.5%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for GRI vs GYRE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GRI vs GYRE — Which Stock Is More Undervalued?

GYRE scores higher with a 8.0/10 quality rating vs GRI's 3.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing GRI Bio, Inc. (GRI) and Gyre Therapeutics, Inc. (GYRE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GRI currently trades at $2.06 with a QOC of 3.9/10, while GYRE trades at $5.91 with a QOC of 8.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).